Home›People›Alon Lazarus
AL

Alon Lazarus

Director at Crossbow Therapeutics. Also a director at Reunion Neuroscience, Auron Therapeutics and Entact Bio.

DirectorPublic companyRoles at 4 startups
Updated Nov 9, 2026·Latest SEC filing Sep 30, 2025·Suggest an edit

About Alon Lazarus

Alon Lazarus is a director at Crossbow Therapeutics.

Form D filings also name Alon Lazarus as a director at Reunion Neuroscience, Auron Therapeutics and Entact Bio.

Alon Lazarus reports to the SEC as a director or major shareholder of 2 public companies: Werewolf Therapeutics (HOWL) and Keros Therapeutics (KROS).

Alon Lazarus first appears on SEC filings in 2020.

Experience

This experience comes from SEC filings. The years are when the filings name Alon Lazarus in the role, so the role may have started earlier or lasted longer.

Crossbow Therapeutics, Inc.
Director
2025 · Cambridge, MA
Reunion Neuroscience, Inc.
Director
2024 – 2025 · Morristown, NJ
Werewolf Therapeutics, Inc.
Director and 10% owner
2021 – 2025 · Public company (HOWL)
Auron Therapeutics, Inc.
Director
2020 – 2024 · Wellesley, MA
Develops potential treatments for people with cancer and inflammatory diseases.
Entact Bio, Inc.
Director
2024 · Watertown, MA
Develops medicines that enhance protein function for people with diseases.
Keros Therapeutics, Inc.
Director and 10% owner
2020 · Public company (KROS)

Key Colleagues at Startups

The people Alon Lazarus works with at each company, as listed on that company's latest Form D.

Crossbow Therapeutics, Inc. · Form D, Sep 30, 2025
AN
Alexander Nolte
Executive officer
DW
Dmitri Wiederschain
Executive officer
SA
CB
Charles Baum
Director
Briggs Morrison
Briggs Morrison
Chief Executive Officer and director
IM
TF
Todd Foley
Director
Reunion Neuroscience, Inc. · Form D/A, Sep 9, 2025
GM
Gregory Mayes
Executive officer and director
ME
AG
NS
EL
Ellen Lubman
Director
MP
Mark Pollack
Executive officer
NB
Nathan Bryson
Executive officer
MT
Mark Theeuwes
Executive officer
ES
Edward Smith
Chief Financial Officer
Auron Therapeutics, Inc. · Form D, Dec 31, 2024
Anna French
Anna French
Director
Serge Messerlian
Serge Messerlian
Board Director
KY
Katharine Yen
Founder & CEO, director
Entact Bio, Inc. · Form D/A, May 15, 2024
Victoria Richon
Victoria Richon
CEO, Board Member
OS
Owen Smith
Board Member
Anna French
Anna French
Director
RG
AS

Sources

  1. SECCrossbow Therapeutics, Inc. Form D, filed Sep 30, 2025
  2. SECReunion Neuroscience, Inc. Form D/A, filed Sep 9, 2025
  3. SECAuron Therapeutics, Inc. Form D, filed Dec 31, 2024
  4. SECEntact Bio, Inc. Form D/A, filed May 15, 2024
  5. SECForms 3, 4 and 5 filed by Alon Lazarus (SEC filer 1808244)